Patients with relapsing remitting multiple sclerosis (RRMS) who received Sanofi Genzyme’s Lemtrada (alemtuzumab) experienced effects of treatment on disease activity that were maintained over seven years, according to data from the extension of two pivotal studies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,